DFE Pharma launches new Center of Excellence in Hyderabad

The C2F center is based at Genome Valley in Hyderabad, a hub of major Indian and global (bio) pharmaceutical companies and renowned research organizations.

C2F helps pharmaceutical companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharmaceutical development.

Pharmaceutical companies face increasing challenges such as developing robust formulations which can be scaled up for high-speed production and first launched in the market.

The services offered by this new state-of-the-art facility, are mainly focused on oral solid dosage forms, comprising all types of pre-registration work including development, scale-up, and technology transfer.

Formulation support includes specialized dosage forms such as orally disintegrating, effervescent, chewable, and sublingual tablets, mini tablets.

C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression.

The center works with the active pharmaceutical ingredients (APIs)* and can utilize innovative concepts with model APIs. The equipment covers an instrumented tablet press, an automated capsule filling machine, a tablet coater, a blister packaging machine, stability chambers, and state-of-the-art analytical equipment.

The C2F offering can provide pharmaceutical companies with multiple advantages such as, for example, the aim to significantly lower the number of development cycles and to reduce formulation costs when launching a medicine.

Telangana Minister for Industries and Municipal Administration and Urban Development, Mr K.T. Rama Rao, said: "I'm delighted to welcome DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions in Genome Valley, Hyderabad.

We are happy to support and facilitate the establishment of "Closer to the Formulator" (C2F) with the major objective of helping pharma companies to move up the value chain, he said.

The Government of Telangana will work with DFE Pharma to ensure that Life Sciences companies in the state leverage this facility, he added.

Headquartered in Goch, Germany, DFE Pharma has made a multimillion-euro investment in the new Center in Hyderabad and our overall goal is to help the global and Indian pharmaceutical industry to launch new products fast, at a low cost, and always first-time-right" said Martti Hedman, CEO of DFE Pharma.

"This new Center of Excellence demonstrates how DFE Pharma anticipates trends and innovations to increase patient's access to safe, high-quality medicines", Hedman added.

"Our new C2F center of nearly 1200 m2, offers cutting-edge capabilities and resources to improve product development globally, while also integrating hardware and data management software. Our services result in robust formulations, utilizing top-level excipient expertise transferrable to scale-up. We aim to further collaborate with our customers in this new Center to combine the joint formulation expertise" explained Dr. Anilkumar S. Gandhi, Director of the C2F center.